Reply

I read with interest the recent submission by Taft and Mutlu regarding the use of vedolizumab for the successful treatment of apparent eosinophilic esophagitis (EoE) in a patient with Crohn's disease (CD). This communication, along with a recent clinical observation by Nhu et al,1 suggests a potential novel addition to our therapies for EoE and, as such, is worthy of further interest.

https://ift.tt/2OM7Jnu